KALVISTA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.44 USD | -1.12% |
|
-2.56% | -6.61% |
Presenter SpeechAndrew Fein (Analysts)Hi, everyone. I'm Andrew Fein, one of the biotech analys...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.
Sector
Pharmaceuticals
Calendar
2024-07-03
- Q4 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
11.44
USD
Average target price
30.6
USD
Spread / Average Target
+167.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.61% | 483M | |
| -2.75% | 85.68B | |
| +5.53% | 41.4B | |
| -24.99% | 28.22B | |
| +54.63% | 24.64B | |
| -7.19% | 16.98B | |
| -34.20% | 13.29B | |
| -17.31% | 11.66B | |
| -11.43% | 11.65B | |
| -1.57% | 8.18B |
- Stock Market
- Equities
- KALV Stock
- News KalVista Pharmaceuticals, Inc.
- Transcript : KalVista Pharmaceuticals, Inc. Presents at H.C. Wainwright 1st Annual Hereditary Angioedema Conference, Jul-20-2022
